A Study of Safety, Tolerability and Pharmacokinetics of Apremilast (CC-10004) in Pediatric Subjects With Moderate to Severe Plaque Psoriasis

PHASE2CompletedINTERVENTIONAL
Enrollment

42

Participants

Timeline

Start Date

October 13, 2015

Primary Completion Date

September 4, 2017

Study Completion Date

July 29, 2019

Conditions
Psoriasis
Interventions
DRUG

Apremilast

Trial Locations (18)

10025

Mount Sinai, St. Luke's, New York

22149

Kinderkrankenhaus Wilhelmstift, Dermatologie, Hamburg

28046

Hospital La Paz, Madrid

30322

Emory University, Atlanta

45147

Universitatsklinikum Essen, Essen

48149

Muenster University Hospital (Universitätsklinikum Muenster), Münster

53127

Rheinische Friedrich-Wilhelms-Universitaet Bonn - Universitaetsklinikum Bonn, Bonn

55131

Universitätsmedizin der Johannes Gutenberg-Universität Mainz, Mainz

60118

Dundee Dermatology, West Dundee

60590

Universitatsklinikum Klinikum Frankfurt Main, Frankfurt

60611

Ann & Robert H. Lurie Children's Hospital of Chicago Department of Dermatology, Chicago

78218

Texas Dermatology and Laser Specialists, San Antonio

92123

Rady Children's Hospital, San Diego

T6G 2B7

Stollery Children's Hospital, Edmonton

A1A 5E8

Nexus Clinical Research, St. John's

H3T 1C5

CHU Saint-Justine, Montreal

08041

Hospital de la Santa Creu i Sant Pau, Barcelona

08950

Hospital Sant Joan de Deu, Esplugues de Llobregat

Sponsors

Lead Sponsor

All Listed Sponsors
lead

Amgen

INDUSTRY